The newest agents
The 2023–2026 approvals and frontier agents in the atlas, freshly profiled and grounded in PubMed. The catalog grows continuously — a weekly discovery pass scans the literature for new nephrotoxicity signals.
2025
7 agentsDatopotamab deruxtecan (Dato-DXd)
Antibody-drug conjugate (TROP2/DXd)
Linvoseltamab
BCMA×CD3 bispecific T-cell engager
Mirdametinib
MEK inhibitor
Penpulimab
PD-1 immune checkpoint inhibitor
Sunvozertinib
EGFR exon20 TKI
Vimseltinib
CSF1R tyrosine kinase inhibitor
Zongertinib
HER2 TKI
2024
13 agentsCosibelimab
PD-L1 immune checkpoint inhibitor
Denileukin diftitox
Immunotoxin (IL-2–diphtheria)
Imetelstat
Telomerase inhibitor
Ivonescimab
PD-1 x VEGF bispecific antibody
Lazertinib
EGFR TKI (3rd-gen)
Lifileucel
Tumor-infiltrating lymphocyte (TIL) therapy
Revumenib
Menin inhibitor
Tarlatamab
Bispecific (DLL3×CD3)
Tislelizumab
PD-1 immune checkpoint inhibitor
Tovorafenib
Type II RAF inhibitor
Vorasidenib
Mutant IDH1/2 inhibitor
Zanidatamab
HER2 bispecific antibody
Zolbetuximab
Anti-Claudin-18.2 monoclonal antibody
2023
10 agentsCapivasertib
AKT inhibitor
Elacestrant
Oral selective estrogen-receptor degrader (SERD)
Fruquintinib
VEGFR TKI
Momelotinib
JAK/ACVR1 inhibitor
Nirogacestat
Gamma-secretase inhibitor
Pirtobrutinib
Non-covalent BTK inhibitor
Quizartinib
FLT3 inhibitor
Repotrectinib
ROS1/TRK TKI
Retifanlimab
PD-1 immune checkpoint inhibitor
Toripalimab
PD-1 immune checkpoint inhibitor
Newest approvals shown; the full era breakdown lives on the overview.